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IL = interleukin; MCP-1 = monocyte chemoattractant protein 1; MIP-1α = macrophage inflammatory protein 1α.
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Abstract
In the previous issue of Critical Care, Vermont and colleagues
presented a simple but well-executed observational study
describing the levels of chemokines in the serum of 58 children
with meningococcal sepsis. The chemokine levels correlated with
disease severity and outcome. Significant correlations were
demonstrated between admission chemokine levels and the
Paediatric Risk of Mortality score, the Disseminated Intravascular
Coagulopathy score, the Sequential Organ Failure Assessment
score and laboratory parameters of disease severity. Additionally,
nonsurvivors had much higher levels of chemokines compared with
survivors, and the chemokine levels predicted mortality with a high
degree of sensitivity and specificity. The findings are important as
they indicate a possible mechanism for risk stratification in future
trials of novel therapies in human sepsis, which as yet have not
been successful.
Injection of lipopolysaccharide into volunteers is followed by
acute rises of monocyte-derived proinflammatory cytokines,
including tumour necrosis factor [1], IL-1, and IL-6 [2].
Although the concentration of these cytokines falls to normal
within a few hours, the secondary effects of their release can
be devastating. These effects include fever, leukocyte and
endothelial activation, leukocyte margination and trans-
migration, leukocyte maturation, metabolic and endocrine
effects, and enhanced procoagulant activity at the endothelial
surface — all features of sepsis syndrome. Cytokines are
released into the circulation in human septic shock, and the
levels in both septic shock [3] and meningococcaemia [4,5]
correlate with disease severity and mortality.
Chemoattractant cytokines, or chemokines, also play an
important role in the recruitment and regulation of the
leukocyte traffic during acute inflammatory responses [6].
Chemokines are structurally homologous proteins with a
molecular mass between 6 kDa and 14 kDa, divided into four
subfamilies (CC, CXC, CX3C, and C) on the basis of the
arrangement and number of cysteine motifs. The CC chemo-
kines monocyte chemoattractant protein 1 (MCP-1) and
macrophage inflammatory protein 1α (MIP-1α) are chemo-
attractant for monocytes, whereas the CXC chemokines IL-8
and growth-related ongogenes alpha are chemoattractant for
neutrophils. Chemokine production is induced in monocytes
by lipopolysaccharide from Gram-negative bacteria such as
the meningococcus [7].
There has so far been only one published account of the
chemokine response in meningococcal disease [8]. This
investigation demonstrated that in patients with fulminant
meningococcal septicaemia, MCP-1, MIP-1α, and IL-8 levels
were significantly higher than in cases of distinct meningitis
or mild systemic meningococcal disease and correlated with
plasma lipopolysaccharide concentrations. However, more
formal descriptions of disease severity or outcome were not
provided.
In the previous issue of Critical Care, Vermont and colleagues
presented a simple but well-executed observational study
describing the levels of the chemokines MIP-1α, MCP-1, IL-8
and growth-related ongogenes alpha in the serum of 58
children with meningococcal sepsis [9]. The authors
correlated the level of these chemokines to both disease
severity and outcome. Significant correlations were demon-
strated between admission chemokine levels and the
Paediatric Risk of Mortality score, the Disseminated
Intravascular Coagulopathy score, the Sequential Organ
Failure Assessment score and laboratory parameters of
disease severity. Additionally, nonsurvivors had much higher
levels of chemokines compared with survivors, and
chemokine levels predicted mortality with a high degree of
sensitivity and specificity. Prediction of mortality with
chemokine levels was vastly superior to the prediction with
tumour necrosis factor alpha levels.
Commentary
Meningococcal disease: identifying high-risk cases
David Inwald1 and Mark Peters2
1Paediatric Intensive Care Unit, St Mary’s Hospital, London UK
2Portex Unit, Institute of Child Health, London, UK
Corresponding author: David Inwald, David.Inwald@st-marys.nhs.uk
Published: 16 March 2006 Critical Care 2006, 10:129 (doi:10.1186/cc4873)
This article is online at http://ccforum.com/content/10/2/129
© 2006 BioMed Central Ltd
See related research by Vermont  et al. in issue 10.1 [http://ccforum.com/content/10/1/R33]Page 2 of 2
(page number not for citation purposes)
Critical Care    Vol 10 No 2 Inwald and Peters
There are some limitations of the study; no control group of
other critically ill children was included and, of the 58 patients
included, 38 were involved in a placebo-controlled dose-
finding study of protein C concentrate [10]. Although the
involvement of patients in the protein C study may have had
some impact on the chemokine levels measured at 24 hours,
most of the paper is taken up with an investigation of
chemokine levels at admission to the paediatric intensive care
unit, which will have been unaffected by protein C
administration. Additionally, the extent of the changes in
chemokine concentrations and the correlations seen were so
impressive as to mitigate against the absence of a control
group of cases of children without meningococcal disease.
The findings are important because they are consistent with
the current view of the pathophysiology of severe sepsis and
of the redundancy built into the inflammatory response. They
also indicate another potential mechanism for risk
stratification in future trials of novel therapies in sepsis.
Previous trials of immunomodulatory therapy in sepsis,
performed in the 1990s, were not successful. Trials of
recombinant bactericidal/permeability-increasing protein and
recombinant human activated protein C have more recently
also failed to demonstrate any benefit [11,12]. Inclusion of
too many low-risk patients may have contributed to the failure
of these trials.
Risk stratification should ideally include considerations of
timing, disease severity and of the proinflammatory or anti-
inflammatory state but should also be immediately available at
the bedside [13]. Standard tests such as neutropaenia and
thrombocytopaenia may currently offer the best risk
stratification [14], but the study of Vermont and colleagues
raises the potential for specific risk assessment by looking at
levels of chemokines.
The search for specific groups of patients likely to benefit
from novel therapies will be critical for future trials. As Grau
and Maennel stated in the 1990s, the key will be to ‘inject the
right inhibitor, at the right dose, in the right patient subgroup
and most importantly in the right time window’ [15]. To do
this effectively, it is necessary to define who will benefit from
therapy by elucidating the basic mechanisms of the host
response to infection and the subgroups of patients most
likely to respond to therapy. Only then will a logical approach
to reducing the mortality from sepsis, both meningococcal
and otherwise, be possible.
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